Private Client Services LLC Makes New $301,000 Investment in Bristol-Myers Squibb (NYSE:BMY)

Private Client Services LLC purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,864 shares of the biopharmaceutical company’s stock, valued at approximately $301,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $25,000. True Wealth Design LLC acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $26,000. Milestone Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $27,000. Coppell Advisory Solutions LLC acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth $28,000. Finally, Blue Bell Private Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 200 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $48.54 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The company’s 50-day simple moving average is $51.29 and its 200-day simple moving average is $51.69. The stock has a market capitalization of $98.38 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 1.78 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The business had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. During the same quarter last year, the company posted $1.82 earnings per share. The company’s quarterly revenue was up .6% compared to the same quarter last year. Equities analysts anticipate that Bristol-Myers Squibb will post 5.41 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.94%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analysts Set New Price Targets

A number of analysts have recently commented on BMY shares. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Wells Fargo & Company lowered their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a report on Tuesday, February 6th. Finally, StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.